Priveterra Acquisition Corp. (NASDAQ:PMGM) and its biopharmaceutical target, AEON Biopharma, announced this morning that they have secured an additional $20 million in commitments from existing investors in connection to its business combination.
The SPAC brought about $276 million into the deal through its current trust but aside from today’s funding, it has not yet supplemented this with other committed sources of capital. Priveterra must maintain at least $45 million in cash available in order for the deal to close, which means the SPAC potentially still needs to secure an additional $25 million in capital.
Under the terms of the commitments, the issued security is to be exchanged or converted into Class A common stock of the combined company once the proposed merger is completed, and is expected to fund concurrently with or immediately prior to the closing of the deal.
PMGM announced its $201.8 million business combination with drug developer AEON on December 13, 2022. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.
AEON Biopharma also announced in December the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of episodic migraine. The company expects to announce top-line data from the study in the second half of 2023.
At the SPAC of Dawn Another day, another wave of trade war news as US President Donald Trump has announced fresh 25% tariffs on all imported automobiles on April 3 in addition to the new customs duties expected to come into force on April 2. These moves cut across a wide swath of SPAC target...
Armada Acquisition Corp. II has filed for a $200 million SPAC to combine with a fintech, SaaS or AI company with nearly the same team top-to-bottom that just completed its first SPAC combination in that space. The filing is Cohen & Company’s seventh of the year as left-lead underwriter and Northland Capital Markets is stepping in...
HCM II (NASDAQ:HOND) has entered into a definitive agreement to combine with nuclear reactor developer Terrestrial Energy at a pro forma equity value of $1.3 billion. Charlotte, North Carolina-based Terrestrial is developing unique molten salt nuclear reactors designed to generate enhanced heat outputs for industrial client processes. The combined company is expected to trade on...
At the SPAC of Dawn Rain or shine, legal challenges for SPACs do not appear to be going anywhere. Cornerstone Research found this week that the number of securities class action lawsuit settlements increased +6% in 2024 and suits targeted at SPACs or de-SPACs represented 19% of this total. On the plus side, the median...
At the SPAC of Dawn A new conservative stock with meme potential is further taking shape as the market finds its footing this week. Firearms marketplace GrabAGun nominated its Board that will take their seats after the company completes its combination with Colombier II (NYSE:CLBR) anticipated later this summer. This Board includes Donald Trump Jr.,...